What does Vertex Pharmaceuticals, Inc. do?

Vertex Pharmaceuticals, Inc. focuses on discovering and commercializing medicines for serious diseases, primarily cystic fibrosis. As of March 2025, it reported net sales of $2.746 billion and a net profit of $646 million, with a market cap of approximately $113.5 billion.

Overview:<BR>Vertex Pharmaceuticals, Inc. is engaged in discovering, developing, manufacturing, and commercializing medicines for serious diseases, primarily focusing on therapies for cystic fibrosis, and operates within the Pharmaceuticals & Biotechnology industry with a large-cap market valuation.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,746 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 646 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 113,501.78 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: NA <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.38 <BR>Return on Equity: -3.39% <BR>Price to Book: 6.88<BR><BR>Contact Details:<BR>Address: 50 Northern Ave, BOSTON MA: 02210-1862 <BR>Tel: ['1 617 3416393', '1 617 9616108'] <BR>Website: https://www.vrtx.com/

Should I buy, sell or hold Vertex Pharmaceuticals, Inc.?

Who are in the management team of Vertex Pharmaceuticals, Inc.?

As of March 2022, the management team of Vertex Pharmaceuticals, Inc. is led by Dr. Jeffrey Leiden (Executive Chairman) and Dr. Reshma Kewalramani (President and CEO), along with several independent directors including Mr. Bruce Sachs, Dr. Sangeeta Bhatia, Mr. Lloyd Carney, Dr. Alan Garber, and Mr. Terrence Kearney.

As of March 2022, the management team of Vertex Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Jeffrey Leiden, who serves as the Executive Chairman of the Board.<BR>- Dr. Reshma Kewalramani, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Bruce Sachs, who is the Co-Lead Independent Director.<BR>- Dr. Sangeeta Bhatia, who is an Independent Director.<BR>- Mr. Lloyd Carney, who is also an Independent Director.<BR>- Dr. Alan Garber, who serves as an Independent Director.<BR>- Mr. Terrence Kearney, who is an Independent Director.<BR><BR>In summary, the management team is led by Dr. Jeffrey Leiden and Dr. Reshma Kewalramani, with several independent directors contributing to the board.

Is Vertex Pharmaceuticals, Inc. overvalued or undervalued?

As of August 4, 2025, Vertex Pharmaceuticals has shifted from a risky to an attractive valuation grade, but it appears overvalued compared to peers, with a year-to-date return of -3.87% and a one-year return of -18.36%, significantly underperforming the S&P 500.

As of 4 August 2025, the valuation grade for Vertex Pharmaceuticals, Inc. has moved from risky to attractive, indicating a positive shift in its investment appeal. Despite this improvement, the company appears to be overvalued, particularly when considering its Price to Book Value of 7.01 and the EV to Sales ratio of 9.91, which are significantly higher than those of its peers. For instance, Merck & Co., Inc. has a more favorable EV to EBITDA of 12.15, while Pfizer Inc. stands out with an EV to EBITDA of 11.07, suggesting that Vertex may be priced too high relative to its earnings potential.<BR><BR>In terms of recent performance, Vertex has struggled, with a year-to-date return of -3.87% compared to the S&P 500's 12.22%, and a one-year return of -18.36% against the S&P 500's 17.14%. This underperformance reinforces the notion that the stock may be overvalued in the current market context.

Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, Vertex Pharmaceuticals has a mildly bearish technical trend, with mixed indicators showing underperformance compared to the S&P 500, suggesting limited upward momentum.

As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential for upward movement over a longer time frame. However, the Bollinger Bands and KST are both mildly bearish on both weekly and monthly charts, reinforcing the bearish sentiment. The Dow Theory indicates a mildly bullish stance on the weekly but is mildly bearish on the monthly.<BR><BR>In terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of 0.05% compared to the S&P 500's 14.18%, and a one-year return of -11.51% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, with key indicators like the MACD and KST contributing to this outlook.